The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Novel therapies have achieved unprecedented benefit in survival of advanced melanoma patients. While immunotherapy (ICI) can be administered independent of mutational status, BRAF and MEK kinase inhibitors represent another effective treatment option for patients with BRAF mutant melanoma. Given the...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Dummer, Reinhard, Welti, Michèle, Ramelyte, Egle
Aineistotyyppi: Online Artikkeli Teksti
Kieli:English
Julkaistu: BioMed Central 2023
Aiheet:
Commentary
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403899/
https://www.ncbi.nlm.nih.gov/pubmed/37543586
http://dx.doi.org/10.1186/s12967-023-04391-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403899/
https://www.ncbi.nlm.nih.gov/pubmed/37543586
http://dx.doi.org/10.1186/s12967-023-04391-1

Samankaltaisia teoksia